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Edited by Robert BaroukiAbstract Insulin and glucose inhibited apoptosis in the MIN6
insulin-secreting cell line. The protective eﬀect of 25 mM glucose
was prevented by an anti-insulin antibody and this antibody-
induced increase in apoptosis was reversed by the presence of ex-
cess insulin. Glucose stimulated MIN6 cell proliferation and this
was inhibited by blockade of insulin secretion, by an anti-insulin
antibody and by phosphatidylinositol-3 kinase (PI-3K) inhibi-
tion. Furthermore, MIN6 cell proliferation was stimulated by
depolarising concentrations of KCl and by insulin itself. These
data indicate that insulin secreted by b-cells in response to ele-
vated glucose exerts autocrine eﬀects to protect against apopto-
sis and stimulate proliferation, and suggest that the insulin
signalling cascade, through the PI-3K pathway, may be an eﬀec-
tive means of maintaining b-cell mass in diabetes.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Decreased b-cell mass has been identiﬁed in pancreatic sec-
tions from Type 2 diabetic subjects [1,2] and may be an impor-
tant causal factor of Type 2 diabetes mellitus (T2DM).
Regulation of b-cell mass is largely a balance between b-cell
replication and apoptosis, and when apoptosis exceeds replica-
tion (or neogenesis) then mass reduction ensues. The reduc-
tions in b-cell mass in T2DM arise through increased
apoptosis, with the frequency of apoptosis up to 10-fold higher
in pancreatic tissue from individuals with T2DM than in non-
diabetic subjects [2]. Studies using transgenic animals allow in-
creased understanding of the signalling pathways involved in
the b-cell failure. Thus, knockout of insulin receptor sub-
strate-2 (IRS-2) in mice caused T2DM through profound
reductions in b-cell mass [3] and this could be prevented by
b-cell targeted expression of IRS-2 [4]. The importance of
b-cell insulin receptors in maintaining b-cell mass was demon-
strated by inactivation of the insulin receptor (IR) gene in b-
cells which led to marked defects in postnatal b-cell growth [5].
Insulin is a growth factor, so decreased insulin-driven b-cell
proliferation in IR- and IRS-2 deﬁcient mice could explain the
reductions in b-cell mass seen in these models. However, insu-*Corresponding author. Fax: +44 207848 6280.
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decreased b-cell mass of b-cell targeted IR knockout mice [5]
and IRS-2 disrupted mice [3] is also consistent with insulin
exerting anti-apoptotic eﬀects in b-cells. Such a mode of action
of insulin is supported by recent studies in which transgenic
mice deﬁcient in b-cell receptors for insulin and insulin-like
growth factor (IGF-1) showed both reduced b-cell mass and
increased islet TUNEL staining, indicative of enhanced apop-
tosis [9].
Thus, it is possible that insulin exerts direct eﬀects on b-cells
to regulate b-cell number through a combination of reduced
apoptosis and increased replication. Glucose protects b-cells
against apoptosis [10] and stimulates b-cell proliferation [11],
and it may regulate these functions through the secretion of
insulin. Recent in vivo studies provide evidence for a role of
the phosphatidylinositol-3 kinase (PI-3K) pathway, which is
activated by insulin, in regulating b-cell mass. Thus, it has been
suggested that b-cell deletion of PTEN (phosphatase with ten-
sin homology) led to constitutive activation of PI-3K together
with increased islet mass and protection from apoptosis [12].
However, despite data from transgenic animal studies impli-
cating the insulin signalling cascade in maintaining b-cell mass
there is little direct evidence that b-cell insulin receptors are di-
rectly coupled to decreased b-cell apoptosis or increased prolif-
eration.
In the current study, we have therefore examined the eﬀects
of exogenous insulin on apoptosis and proliferation in the
MIN6 insulin-secreting cell line, determined whether insulin
released in response to glucose can exert autocrine anti-apop-
totic and pro-proliferative eﬀects in b-cells, and examined the
role of PI-3K in b-cell apoptosis and proliferation.2. Materials and methods
2.1. Materials
MIN6 cells were a kind gift from Dr. Y. Oka and Professor J.-I.
Miyazaki (then at University of Tokyo, Japan). All tissue culture re-
agents, insulin, IGF-1 and N-Acetyl-Asp-Glu-Val-Asp p-nitroanilide
(DEVD) were purchased from Sigma–Aldrich (Dorset, UK). The
Anti-IGF-1 antibody and cis-diaminedichloroplatinum (cis-Pt) were
from Merck Biosciences (Nottingham, UK) and LY294002 was from
Tocris Bioscience (Bristol, UK). The anti-insulin antibody was from
Santa Cruz biotechnology (Heidelberg, Germany). The colorimetric
BrdU cell proliferation ELISA was obtained from Boehringer Mann-
heim (Mannheim, Germany).
2.2. Methods
2.2.1. DNA fragmentation. MIN6 cells were serum- and glucose-
deprived for 24 h (DMEM, 2.5 mM glucose, no serum) then main-
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Fig. 1a. Insulin protects against cis-Pt-induced MIN6 cell DNA
fragmentation. One hundred micromolar cis-Pt induced generation of
nucleosome fragments in MIN6 cells that produced DNA ‘‘ladder’’
patterns on ethidium-bromide-stained agarose gels, and this was
reduced in a concentration-dependent manner by insulin (1–10 lM).














6978 D. Muller et al. / FEBS Letters 580 (2006) 6977–6980the presence of the pro-apoptotic agent cis-Pt (100 lM) in the absence
or presence of insulin (1–10 lM). 50 lg of DNA isolated from each
treatment group was resolved on 2% agarose gels and visualised by
ethidium bromide staining.
2.2.2. Caspase-3 assay. MIN6 cells were serum- and glucose-de-
prived for 24 h (DMEM, 2.5 mM glucose, no serum) then maintained
in culture overnight in DMEM (25 mM glucose, no serum) with
100 lM cis-Pt in the absence or presence of insulin (100 pM to
10 lM) or IGF-1 (1 pM to 100 nM). In some experiments serum-
and glucose-deprived MIN6 cells were exposed to a range of glucose
concentrations (2.5–25 mM, 48 h) in the absence of cis-Pt. In other
experiments the medium was supplemented with anti-insulin (1 lg/
ml) or anti-IR (1 lg/ml) antisera or LY294002 (50 lM). Cells were
lysed, protein content was quantiﬁed by the Bradford assay and
caspase-3 activity was measured in 50 lg of MIN6 cell protein by
spectrophotometric (405 nm) detection of cleavage of the chromo-
phore p-nitroanilide from the substrate DEVD. Data are expressed
as a percentage of maximal absorbance at 405 nm in the presence of
100 lM cis-Pt, or as a percentage of absorbance at 2.5 mM glucose.
2.2.3. Proliferation assay. MIN6 cells were serum- and glucose-de-
prived for 24 h (DMEM, 2.5 mM glucose, no serum) then maintained
in culture in DMEM (no serum) supplemented with 2.5–25 mM glu-
cose for 48 h, in the absence or in the presence of insulin (0.5–
500 nM). In some experiments the medium was supplemented with
anti-insulin (1 lg/ml) or anti-IGF-1 (1 lg/ml) antisera, KCl (20–
50 mM), nifedipine (1–20 lM) or LY294002 (5–50 lM). Proliferation
was quantiﬁed by measuring the rate of BrdU incorporation into cel-
lular DNA, essentially as previously described [13]. Data are expressed
as absorbance at 450 nm or as a percentage of maximal absorbance at
25 mM glucose plus 10% serum, with subtraction of a blank at 1 mM
glucose.
2.2.4. Data analysis. Numerical data are expressed as means ±
S.E.M. Diﬀerences between treatments were analysed by ANOVA or
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Fig. 1b. Insulin and IGF-1 inhibit cis-Pt-induced caspase-3 activation.
Insulin (r, 100 pM to 10 lM) and IGF-1 (h, 1 pM to 100 nM)
produced concentration-dependent reductions in 100 lM cis-Pt-
induced caspase-3 activity in MIN6 cells. Data are means ± S.E.M.,
n = 3, P < 0.001 by ANOVA for insulin and IGF-1.3. Results and discussion
3.1. Insulin protects against apoptosis in MIN6 insulin-secreting
cells
During the terminal stages of apoptotic cell death activated
endonucleases cleave chromatin to generate nucleosome frag-
ments that produce ‘‘ladder’’ patterns when electrophoresed
on agarose gels. In the absence of cis-Pt nucleosomes were
not visible on the ethidium bromide-stained agarose gel
(Fig. 1a) indicating negligible apoptosis. However, DNA frag-
mentation was clearly visible after overnight exposure of
MIN6 cells to 100 lM cis-Pt and insulin (1–10 lM) produced
a concentration-dependent protection against apoptosis in
these cells, although some cis-Pt-induced nucleosome ladder-
ing was still visible in the presence of 10 lM insulin.
The anti-apoptotic eﬀect of insulin in MIN6 cells was con-
ﬁrmed by measurements of the activity of caspase-3, an eﬀec-
tor caspase that cleaves downstream targets and whose
activation irreversibly commits cells to apoptosis. Apoptosis
was induced by overnight exposure of MIN6 cells to 100 lM
cis-Pt, and it can be seen from Fig. 1b that insulin reduced cas-
pase-3 activity in a concentration-dependent manner, such that
it was decreased by approximately 40% in the presence of
10 lM insulin. This is consistent with the residual cis-Pt-in-
duced DNA laddering observed in the presence of 10 lM insu-
lin, as seen in Fig. 1. Fig. 1b also shows that IGF-1 inhibited
cis-Pt-stimulated caspase-3 activity. IGF-1 was more potent
than insulin and produced a greater maximal protective eﬀect.
The combined presence of 100 nM insulin and 100 nM IGF-1
did not produce a greater protection against apoptosis than
that observed when each agonist was administered separately.3.2. Role of insulin in the anti-apoptotic eﬀects of glucose in
MIN6 insulin-secreting cells
Fig. 2a shows that caspase-3 activity was highest in MIN6
cells maintained for 48 h in culture medium containing
2.5 mM glucose and that increasing glucose concentrations re-
sulted in progressive inhibition of caspase-3 activity (P < 0.01).
It can be seen from Fig. 2b that maintenance of MIN6 cells for
48 h at 25 mM glucose in the presence of an anti-insulin anti-
body resulted in signiﬁcant (P < 0.05) increases in caspase-3
activity, to levels not signiﬁcantly diﬀerent to those obtained
at 2.5 mM glucose (107.9 ± 13.4% of 2.5 mM glucose activity,
P > 0.2, n = 3). The increased apoptosis in the presence of the
anti-insulin antibody could be almost completely reversed by
the presence of 5lM insulin (Fig. 2b). The involvement of
the insulin signalling cascade in the anti-apoptotic eﬀect of glu-
cose was further demonstrated by increased apoptosis in the
presence of 1 lg/ml of an anti-IR antibody (caspase activity,
2 mM glucose: 0.17 ± 0.01 absorbance units; 12 mM glucose:


























Fig. 2a. Glucose protects MIN6 cells against apoptosis. Exposure of
MIN6 cells to glucose (2.5–25 mM) produced a concentration-depen-
dent decrease in caspase-3 activity. Data are means + S.E.M., n = 5-9,
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Fig. 2b. The protective eﬀect of glucose on MIN6 cell apoptosis is
dependent on secreted insulin. The decrease in MIN6 cell caspase-3
activity observed when increasing the glucose concentration from 2.5
to 25 mM glucose was inhibited by co-incubation of MIN6 cells with
an anti-insulin antibody. The increase in caspase-3 activity in the
presence of the anti-insulin antibody was signiﬁcantly reduced by the
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Fig. 3. Glucose-stimulated MIN6 cell proliferation is dependent on
secreted insulin. BrdU labelling of MIN6 cell nuclei at both 12 mM
and 25 mM glucose was signiﬁcantly inhibited by co-incubation with
an anti-insulin antibody, but not with an anti-IGF-1 antibody. Data








































Fig. 4a. MIN6 cell proliferation is modulated by regulation of insulin
secretion. BrdU labelling of MIN6 cell nuclei at a sub-stimulatory
glucose concentration (2.5 mM) was stimulated by 20 mM and 50 mM
KCl and proliferation induced by 12 mM glucose was inhibited by
blockade of voltage-operated calcium channels with 1 lM and 20 lM
nifedipine. Data are means + S.E.M., n = 3, *P < 0.05.
D. Muller et al. / FEBS Letters 580 (2006) 6977–6980 69790.04; means ± S.E.M., n = 3; P < 0.05 12 mM glucose versus
12 mM glucose + IR antibody). In addition, the protective ef-
fects of glucose were abolished by inhibition of PI-3K with the
selective inhibitor LY294002 (caspase activity, 12 mM glucose:
0.08 ± 0.01 absorbance units; +50 lM LY294002: 0.20 ± 0.01
means ± S.E.M., n = 3; P < 0.05), suggesting an anti-apoptotic
role for PI-3K downstream of insulin receptor activation.
3.3. Eﬀects of glucose and insulin on MIN6 cell proliferation
Glucose produced a concentration-dependent increase in
BrdU labelling of MIN6 cell nuclei, with maximal eﬀects at
25 mM glucose (BrdU Incorporation, 2.5 mM glucose:
1.76 ± 0.04 absorbance units; 12 mM glucose: 1.95 ± 0.07;
25 mM glucose: 2.02 ± 0.03; means ± S.E.M., n = 8; P <
0.001). MIN6 cell proliferation at both 12 mM and 25 mM
glucose was signiﬁcantly inhibited by co-incubation of the cells
with 1 lg/ml anti-insulin antibody, but not by the same con-
centration of an anti-IGF-1 antibody (Fig. 3). Further supportfor the involvement of secreted insulin in MIN6 cell prolifera-
tion was provided by experiments in which depolarisation of
b-cells with 20 mM or 50 mM KCl caused signiﬁcant increases
in proliferation at 2.5 mM glucose and proliferation induced
by 12 mM glucose was inhibited following blockade of volt-
age-operated calcium channels with nifedipine (Fig. 4a), a
treatment that is known to inhibit glucose-stimulated insulin
secretion. Fig. 4b shows that exogenous insulin (100 nM) stim-
ulated MIN6 cell proliferation at 2.5 mM glucose, but did not
potentiate the stimulatory eﬀects of 12 mM or 25 mM glucose.
These data are consistent with those in Figs. 3 and 4a and,
taken together, suggest that glucose-stimulated MIN6 cell pro-
liferation is completely dependent on the release of insulin.
Furthermore, our observations that glucose-stimulated BrdU
incorporation was inhibited by LY294002 (BrdU Incorpora-
tion, 12 mM glucose: 1.74 ± 0.11 absorbance units; +5 lM



































Fig. 4b. Insulin stimulates MIN6 cell proliferation. One hundred
nanomolar insulin signiﬁcantly increased BrdU incorporation into
MIN6 cell nuclei at 2.5 mM glucose, but was without signiﬁcant eﬀect
at 12 and 25 mM glucose. Data are means + S.E.M., n = 3, *P < 0.05.
6980 D. Muller et al. / FEBS Letters 580 (2006) 6977–6980+50 lM LY294002: 0.69 ± 0.09; means ± S.E.M., n = 8;
P < 0.001) are consistent with secreted insulin stimulating
MIN6 cell proliferation through activation of the PI-3K path-
way.
In conclusion, we have shown here that glucose protects b-
cells against apoptosis and stimulates b-cell proliferation, con-
ﬁrming earlier reports [10,11], and we have now identiﬁed that
insulin plays a major role in mediating these b-cell protective
eﬀects of glucose. Thus, exogenous insulin inhibited apoptosis
and stimulated proliferation in b-cells, glucose-induced inhibi-
tion of b-cell caspase-3 activity and stimulation of BrdU label-
ling of MIN6 cell nuclei were both inhibited by blockade of
insulin signaling and use of a selective inhibitor implicated
PI-3K as being a downstream eﬀector of both the anti-apopto-
tic and pro-proliferative eﬀects of glucose. Further support for
a direct protective eﬀect of insulin in b-cells is provided by the
UKPDS 57 study that showed that early insulin therapy in
individuals with newly diagnosed T2DM was more eﬀective
than introducing insulin only when oral hypoglycaemic ther-
apy had failed [14]. Such clinical observations, together with
the data presented here, suggest that development of agents
that activate the insulin signalling cascade in b-cells could have
therapeutic application to maintain b-cell mass in diabetes.
Acknowledgement: We gratefully acknowledge The Eli Lilly Interna-
tional Foundation for Grant support.References
[1] Sakuraba, H., Mizukami, H., Yagihashi, N., Wada, R., Hanyu,
C. and Yagihashi, S. (2002) Reduced b-cell mass and expressionof oxidative stress-related DNA damage in the islet of Japanese
Type II diabetic patients. Diabetologia 45, 85–96.
[2] Butler, A.E., Janson, J., Soeller, W.C. and Butler, P.C. (2003)
Increased b-cell apoptosis prevents adaptive increase in b-cell
mass in mouse model of type 2 diabetes: evidence for role of islet
amyloid formation rather than direct action of amyloid. Diabetes
52, 2304–2314.
[3] Withers, D.J., Gutierrez, J.S., Towery, H., Burks, D.J., Ren, J.M.,
Previs, S., Zhang, Y., Bernal, D., Pons, S., Shulman, G.I.,
Bonner-Weir, S. and White, M.F. (1998) Disruption of IRS-2
causes type 2 diabetes in mice. Nature 391, 900–904.
[4] Hennige, A.M., Burks, D.J., Ozcan, U., Kulkarni, R.N., Ye, J.,
Park, S., Schubert, M., Fisher, T.L., Dow, M.A., Leshan, R.,
Zakaria, M., Mossa-Basha, M. and White, M.F. (2003) Upreg-
ulation of insulin receptor substrate-2 in pancreatic beta cells
prevents diabetes. J. Clin. Invest. 112, 1521–1532.
[5] Otani, K., Kulkarni, R.N., Baldwin, A.C., Krutzfeldt, J., Ueki,
K., Stoﬀel, M., Kahn, C.R. and Polonsky, K.S. (2004) Reduced b-
cell mass and altered glucose sensing impair insulin-secretory
function in betaIRKO mice. Am. J. Physiol. Endocrinol. Metab.
286, E41–E49.
[6] Nakazawa, T., Chiba, T., Kaneko, E., Yui, K., Yoshida, M. and
Shimokado, K. (2005) Insulin signaling in arteries prevents
smooth muscle apoptosis. Arterioscler. Thromb. Vasc. Biol. 25,
760–765.
[7] Srinivasan, S., Ohsugi, M., Liu, Z., Fatrai, S., Bernal-Mizrachi, E.
and Permutt, M.A. (2005) Endoplasmic reticulum stress-induced
apoptosis is partly mediated by reduced insulin signaling through
phosphatidylinositol 3-kinase/Akt and increased glycogen syn-
thase kinase-3beta in mouse insulinoma cells. Diabetes 54, 968–
975.
[8] Yu, X.R., Jia, G.R., Gao, G.D., Wang, S.H., Han, Y. and Cao,
W. (2006) Neuroprotection of insulin against oxidative stress-
induced apoptosis in cultured retinal neurons: involvement of
phosphoinositide 3-kinase/Akt signal pathway. Acta Biochim.
Biophys. Sin. (Shanghai) 38, 241–248.
[9] Ueki, K., Okada, T., Hu, J., Liew, C.W., Assmann, A., Dahlgren,
G.M., Peters, J.L., Shackman, J.G., Zhang, M., Artner, I., Satin,
L.S., Stein, R., Holzenberger, M., Kennedy, R.T., Kahn, C.R.
and Kulkarni, R.N. (2006) Total insulin and IGF-I resistance in
pancreatic beta cells causes overt diabetes. Nat. Genet. 38, 583–
588.
[10] Hoorens, A., Van de, C.M., Kloppel, G. and Pipeleers, D. (1996)
Glucose promotes survival of rat pancreatic beta cells by
activating synthesis of proteins which suppress a constitutive
apoptotic program. J. Clin. Invest. 98, 1568–1574.
[11] Bonner-Weir, S., Deery, D., Leahy, J.L. and Weir, G.C. (1989)
Compensatory growth of pancreatic beta-cells in adult rats after
short-term glucose infusion. Diabetes 38, 49–53.
[12] Nguyen, K.-T., Tajmir, P., Lin, C.H., Liadis, N., Zhu, X.-D.,
Eweida, M., Tolasa-Karaman, G., Cai, F., Wang, R., Kitamura,
T., Belsham, D.D., Wheeler, M.B., Suzuki, A., Mak, T.W. and
Woo, M. (2006) Essential role of Pten in body size determination
and pancreatic b-cell homeostasis in vivo. Mol. Cell. Biol. 26,
4511–4518.
[13] Luther, M.J., Hauge-Evans, A., Souza, K.L., Jorns, A., Lenzen,
S., Persaud, S.J. and Jones, P.M. (2006) MIN6 b-cell–b-cell
interactions inﬂuence insulin secretory responses to nutrients and
non-nutrients. Biochem. Biophys. Res. Commun. 343, 99–104.
[14] Wright, A., Burden, A.C., Paisey, R.B., Cull, C.A. and Holman,
R.R. (2002) Sulfonylurea inadequacy: eﬃcacy of addition of
insulin over 6 years in patients with type 2 diabetes in the UK.
Prospective Diabetes Study (UKPDS 57). Diabetes Care 25, 330–
336.
